S. Nand

H. Messmore, S. Nand, W. Wehrmacher, 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

J. Radich, F. Ravandi, M. Othus, 2018, Blood.

Genetics of Hypercoagulable and Hypocoagulable States.

A. Natarajan, S. Nand, Daulath Singh, 2018, Neurosurgery clinics of North America.

Hepatitis C virus infection and lymphoproliferative disorders.

D. V. van Thiel, L. R. Peña, N. De Maria, 2000, Digestive diseases and sciences.

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI

E. Estey, R. Hills, N. Russell, 2016, Haematologica.

Congenital Coagulation Disorders

S. Nand, D. Sterrenberg, 2016 .

Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.

R. Fisher, R. Salgia, S. Fisher, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inherited Thrombophilia and the Eye

C. Czerlanis, S. Nand, W. Jay, 2008, Seminars in ophthalmology.

Hemostasis in malignancy

H. Messmore, S. Nand, 1990, American journal of hematology.

Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation.

E. Jaffe, R. Ketterling, J. Maleszewski, 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Herpes zoster during treatment with arsenic trioxide

S. Nand, T. Tanvetyanon, 2004, Annals of Hematology.

A phase II trial of interleukin‐2 in myelodysplastic syndromes

J. Sosman, W. Stock, P. Stiff, 1998, British journal of haematology.

Primary lymphoma of the heart. Prolonged survival with early systemic therapy in a patient

R. Moncada, R. Moncada, G. Mullen, 1991, Cancer.

Pulmonary hypertension in polycythemia vera

S. Nand, E. Orfei, 1994, American journal of hematology.

Neurotoxicity associated with systemic high-dose cytosine arabinoside.

R. Fisher, S. Fisher, H. Messmore, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leukemic transformation in polycythemia vera: Analysis of risk factors

R. Fisher, S. Fisher, H. Messmore, 1990, American journal of hematology.

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

J. Radich, F. Ravandi, M. Othus, 2016 .

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies

E. Estey, F. Appelbaum, G. Garcia-Manero, 2018, Leukemia.

A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.

R. Fisher, J. Sosman, S. Nand, 1994, Blood.

A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all‐trans retinoic acid) therapy

S. Alkan, S. Nand, K. Barton, 2006, European journal of haematology.

γ-δ T-Cell Lymphoma With Disseminated Intravascular Coagulation and Autoimmune Hemolytic Anemia.

S. Nand, Shikha Jain, S. Alsunaid, 2016, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Overcoming Recurrent Cutaneous Reactions from Imatinib Using Once-Weekly Dosing

S. Nand, T. Tanvetyanon, 2003, The Annals of pharmacotherapy.

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

W. Stock, S. Nand, J. Godwin, 1996, American journal of hematology.

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

R. Hills, K. Kerr, N. Russell, 2022, Leukemia & lymphoma.

Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis.

S. Nand, 1993 .

Plasmapheresis in the management of heparin‐associated thrombocytopenia with thrombosis

J. A. Robinson, John A. Robinson, S. Nand, 1988, American journal of hematology.

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

P. Stiff, P. Rajakumar, Raymond Lee, 2020, Blood.

Myelodysplastic Syndromes: Approach to Diagnosis and Treatment

S. Nand, H. Schumacher, 1995 .

Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition

S. Alkan, K. F. Izban, T. Maududi, 2005, American journal of hematology.

Hypercellular bone marrow in aplastic anemia: A case report of two patients

S. Nand, F. Esmail, K. Mirza, 2021, Clinical case reports.

Anaplastic large cell lymphoma involving the urinary bladder: A case report and review of the literature

M. Quek, G. Barkan, A. Kini, 2015, Diagnostic cytopathology.

Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.

Scott E. Smith, P. Stiff, S. Nand, 2006 .

REVIEW: Hepatitis C Virus Infection and Lymphoproliferative Disorders

D. V. van Thiel, L. R. Peña, N. De Maria, 2000, Digestive Diseases and Sciences.

Hirudin therapy for heparin‐associated thrombocytopenia and deep venous thrombosis

S. Nand, 1993, American journal of hematology.

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

K. Pierce, J. Vermette, C. Abboud, 2018, Leukemia & lymphoma.

Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding

A. Keshavarzian, S. Nand, T. Demos, 1996, Abdominal Imaging.

Heckathorn disease revisited.

A. Kini, S. Nand, K. Barton, 2014, Blood.

Intravascular Large B-Cell Lymphoma

S. Nand, Maria Khan, Mark D McCubbin, 2014, Journal of investigative medicine high impact case reports.

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

D. Howard, F. Appelbaum, C. Willman, 2013, Blood.

Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling

Jiwang Zhang, P. Breslin, Wei Wei, 2016, Oncotarget.

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

H. Avet-Loiseau, L. Coignet, S. Alkan, 2004, Blood.

Neurological Complications of the Leukemias Across the Ages

S. Nand, S. Berg, 2017, Current Neurology and Neuroscience Reports.

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

N. Zeleznik-Le, J. Radich, Shubin Zhang, 2016, Leukemia research.

FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.

N. Zeleznik-Le, Jiwang Zhang, P. Breslin, 2015, Cell reports.

Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway

P. Breslin, P. Kuo, Jian Li, 2017, Leukemia.

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML

Jiwang Zhang, P. Breslin, Wei Wei, 2014, The Journal of experimental medicine.

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.

M. Grever, F. Appelbaum, E. Kraut, 1999, Leukemia research.

Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.

S. Nand, C. Portell, 2008, Blood.

A phase I/II study of sequential interleukin-3 and granulocyte- macrophage colony-stimulating factor in myelodysplastic syndromes

R. Fisher, J. Sosman, S. Nand, 1994 .

Hemophagocytic Lymphohistiocytosis in Adults: Associated Diagnoses and Outcomes, a Ten-Year Experience at a Single Institution

S. Nand, S. Jumic, Stephen Jumic, 2019, Journal of hematology.

Transient Passovoy defect during a febrile illness

S. Nand, J. O’Keefe, M. Merchut, 1985, American journal of hematology/oncology.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

C. Bloomfield, R. Larson, K. Mrózek, 2019, Leukemia.

Therapeutic plasmapheresis and protein A immunoadsorption in Malignancy: A brief review

R. Molokie, S. Nand, 1990, Journal of clinical apheresis.

Hairy cell leukemia variant developing in a background of polycythemia vera.

S. Alkan, S. Nand, N. Kelly, 2009, Archives of pathology & laboratory medicine.

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Scott E. Smith, S. Alkan, K. Rychlik, 2008, Leukemia & lymphoma.

from Multiple Myeloma Patients and Cell Lines

H. Avet-Loiseau, L. Coignet, S. Alkan, 2016 .

Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.

R. Fisher, S. Fisher, H. Messmore, 1992, Leukemia.

POEMS syndrome associated with polycythemia vera

S. Nand, W. Schulz, D. Domenico, 1989, Cancer.

Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge

S. Nand, K. Barton, 2007, Leukemia & lymphoma.

Proton pump inhibitors and iron deficiency: is the connection real?

S. Nand, T. Tanvetyanon, 2004, Southern medical journal.

Commonly used drugs in hematologic disorders.

S. Nand, Elise Anderes, 2014, Handbook of clinical neurology.

Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.

Scott E. Smith, P. Stiff, S. Nand, 2009 .